
Editor's Note: The 10th West China Tianfu Academic Conference on Urologic Oncology was held in Chengdu from November 5 to 7, 2026. From conventional androgen receptor (AR) inhibitors to AR degraders, and further to combination strategies targeting AR alongside PARP and AKT inhibitors, pharmacological treatment for prostate cancer is shifting from single-target blockade toward coordinated pathway inhibition. However, treatment resistance remains a central challenge that cannot be overlooked. Against this backdrop, Oncology Frontier – UroStream invited Professor Baijun Dong from Renji Hospital, Shanghai Jiao Tong University School of Medicine, to share his insights into promising directions in AR-targeted drug development, combination treatment strategies, and pathways for the international development of innovative drugs originating in China.
01
Oncology Frontier – UroStream
Novel androgen receptor pathway-targeted agents are continuously emerging, and drug development strategies are evolving from conventional AR inhibitors to AR degraders. What do you consider the most noteworthy breakthroughs in the current development of AR pathway-targeted drugs? How can existing treatment resistance be further overcome?
Professor Baijun Dong: In the pharmacological treatment of prostate cancer, AR-targeted therapy has always been one of the major focuses of our clinical and research efforts. The challenge we currently face is that, although we now have novel androgen receptor inhibitors, and these agents have made substantial progress over conventional AR inhibitors in clinical practice, significantly prolonging the duration of effective treatment for metastatic hormone-sensitive prostate cancer (mHSPC), some patients still develop treatment resistance after a period of time.
One reason for resistance is indeed the occurrence of mutations involving AR-related factors. Mutations in the AR pathway are among the major causes of treatment resistance.
Against this background, a new direction is emerging: moving from AR inhibition to AR degradation. PROTAC-based agents are now available that inhibit AR through proteasomal degradation. Early preclinical data have been very promising. Several clinical studies are underway both internationally and in China, and our center is also conducting related research. Preliminary Phase I and II clinical data have shown encouraging outcomes, including progression-free survival (PFS). However, whether these drugs can ultimately enter clinical practice will still depend on the results of Phase III trials.
From an international perspective, the available data from some Phase III studies do not currently appear particularly encouraging. Other findings suggest that better outcomes may be achievable through combination therapy or by moving AR degrader treatment to an earlier point in the treatment pathway.
Overall, AR inhibition has already achieved substantial progress in AR-targeted treatment, while whether AR degradation can deliver better clinical outcomes remains to be determined through further research. We look forward to seeing further advances in this field.
02
Oncology Frontier – UroStream
As AR pathway inhibitors are increasingly being introduced earlier in the treatment course of prostate cancer, selecting subsequent treatment after patients progress to the castration-resistant stage has become a new challenge. In your view, what are the most promising directions for exploring combinations of AR pathway-targeted agents with drugs such as PARP inhibitors and AKT inhibitors?
Professor Baijun Dong: As mentioned earlier, AR targeting is undoubtedly one of the most important therapeutic pathways in prostate cancer. With advances in molecular research, particularly analyses of molecular pathways following treatment resistance, we have found that approximately 20%–30% of patients develop alterations in the homologous recombination repair (HRR) pathway, while some also have alterations in pathways such as PTEN and AKT. Based on our previous research, when these pathway alterations are present, they can indeed account for treatment resistance.
Given that these alterations contribute to resistance, combining AR-targeted therapy with drugs targeting HRR, such as PARP inhibitors, is a logical approach. Such combinations have demonstrated favorable efficacy in metastatic castration-resistant prostate cancer (mCRPC), and their use has now moved into the mHSPC setting. The key question currently under discussion is whether these benefits extend to the entire patient population or are limited to patients with specific genetic alterations.
Based on the available data, there is broad agreement that patients with BRCA alterations can achieve prolonged treatment efficacy and reduced resistance when PARP inhibitors are combined with prior AR-targeted therapy. For other HRR genes, such as CDK12 and ATM, moving combinations of AR-targeted therapy and PARP inhibitors into earlier treatment settings has shown a trend toward improved efficacy. However, whether patients with all or only certain genetic alterations can ultimately achieve long-term benefits, such as improved survival, remains under investigation, with further follow-up ongoing.
From the perspective of overcoming treatment resistance in prostate cancer, combination therapy is undoubtedly the trend. This includes AKT inhibitors targeting alterations in the PI3K pathway, such as capivasertib. Long-term follow-up data may be reported this year or next year. Previous findings remain controversial: although short-term efficacy data have demonstrated clinical benefit, we still need to await longer-term results, particularly overall survival (OS) data.
Nevertheless, both theoretical considerations and the experience of treating individual patients suggest that AR-targeted therapy alone may be insufficient for patients with prostate cancer who harbor specific genetic alterations and are prone to treatment resistance and disease progression. Combining AR-targeted therapy with agents directed against these specific molecular pathways may be necessary to prolong the duration of effective treatment, reduce the development of resistance, and ultimately extend overall survival.
03
Oncology Frontier – UroStream
What further efforts do you think are needed for innovative androgen receptor pathway-targeted drugs developed in China to be incorporated into international clinical guidelines?
Professor Baijun Dong: There are now quite a number of novel AR-targeted antiandrogen agents developed in China. Since these drugs entered the domestic market, a considerable number of patients have received treatment with these domestically developed agents. From the perspectives of efficacy, safety, drug accessibility, and price, these drugs are a real boon for patients with prostate cancer in China. They enable patients to access affordable treatments that balance efficacy and safety.
The key to inclusion in international guidelines is having robust evidence-based support, namely clinical research data with a high level of evidence. Some of the novel antiandrogen agents developed in China are already being investigated in international multicenter studies, although the number of patients enrolled outside China remains relatively small. Other domestically developed drugs were not initially included in international multicenter trials and have so far been studied only in domestic multicenter research.
For clinical research data generated in China, including developments in new drug research and the overall use of these agents, to gain recognition from international peers and be incorporated into international guidelines, I believe that, building on the existing foundation of these drugs, we should conduct international multicenter collaborations to explore new indications and clinical settings. On the one hand, this would expand the range of applications and enable more patients to benefit from these drugs. On the other hand, generating such evidence would help these agents gain increasing recognition from the international medical community.
For new drugs that will be developed in the future, we should advocate designing clinical studies as prospective, international multicenter, randomized controlled trials from the very beginning. Based on what we can see today, the results of such studies should be positive. Moreover, these trials would provide the highest level of clinical evidence. I believe that Chinese pharmaceutical companies, novel antiandrogen agents developed in China, and other domestically developed anticancer drugs can all gain recognition from the international medical community through this approach.
